Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease

Volume Parameters Vs Flow Parameters In Assessment Of Reversibility In Stable Chronic Obstructive Pulmonary Disease Patients

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03282526

Enrollment

100

Registered

2017-09-14

Start date

2017-09-30

Completion date

2018-12-31

Last updated

2017-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Brief summary

* Assess the differences between flow and volume responses after bronchodilator reversibility testing in patients over different clinical chronic obstructive pulmonary disease stages (GOLD stage I to GOLD stage IV). * Study the Correlation between the bronchodilator response and the severity of the disease.

Detailed description

chronic obstructive pulmonary disease is a common preventable and treatable disease characterized by persistent airflow limitation that is usually progressive. The diagnosis requires an evidence of obstructive pattern by spirometry measured before and after bronchodilators. The degree of reversibility of airflow obstruction differs between patients, and does not predict the response to bronchodilator therapy. It can be seen in terms of forced vital capacity (FVC) or forced expiratory volume in the first second (FEV1),or Inspiratory capacity (IC) or residual volume (RV).

Interventions

DIAGNOSTIC_TESTWhole body plethysmography

Whole body plethysmography : measure lung volumes Spirometry : to assess severity of chronic obstructive pulmonary disease also reversibility testing

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

40 Years to 60 Years

Healthy volunteers

Inclusion criteria

* Patients Clinical diagnosis of Chronic Obstructive Pulmonary Disease * Must be able to do pulmonary function test * Age more than 40 years * Stable Chronic Obstructive Pulmonary Disease patients

Exclusion criteria

Any patients with a diagnosis of: * Bronchial asthma * Bronchiectasis * Respiratory failure * Decompensated core pulmonale * Chronic Obstructive Pulmonary Disease combined with any other respiratory disease

Design outcomes

Primary

Measure	Time frame	Description
Assess the response pattern to inhaled short acting B2 agonist	twice per day one before inhaled short acting B2 agonist and one after 10 minutes from inhaled short acting B2 agonist for average of 2 year	Assess the response pattern to inhaled short acting B2 agonist through measuring flow and volume parameters to define the differences between volumes responders and flow responders

Contacts

Primary ContactAZZA BAHAA EL-DIN ALI

zozo8928@yahoo.com01090078962

Backup ContactGamal Mohamed Rabie

01221729476

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026